Amphiphilic CyD nanoparticles

A major drawback of j8-CyD for parenteral use is its hemolytic effects due to its interaction with red blood cells, as demonstrated in vitro on erythrocyte suspensions. Studies performed on whole blood and erythrocyte suspension samples show that in all concentrations studied amphiphilic j8-CyD nanospheres are less hemolytic than native j8-CyD, because of their hydrophobic substituents [56]. Besides the hy-drophobicity, the self-assembly of amphiphilic j8-CyDs in the form of nanospheres is also believed to reduce the interaction and direct contact of CyD with red blood cells. 

Antimicrobial activity on Candida albicans ATCC 90028 has been reported for amphiphilic -CyD nanospheres loaded with bifonazole and clotrimazole [56]. When drug-loaded amphiphiUc fi-CyD nanospheres are incubated with C. albicans, a synergistic effect is observed. Indeed, MIC (Minimal Inhibitory Concen- 

Finally, Skiba et al. report the in vivo application of indomethacin-loaded nanocapsules, prepared from amphiphilic jS-CyD substituted on the secondary face by Ce chains, jS-CyDCe, in a rat model [48]. They compared the rat gastric ulcerative effect of encapsulated indomethacin with that of the indomethacin solution (Indoc-id ). Independently of the administered dose, the ulcerative effect was significantly decreased while the bioavailability of indomethacin was maintained. Gastrointestinal ulcer protection by encapsulation of indomethacin in jS-CyDC nanocapsules was 82% for 5 mg kg and 53% for 10 mg kg administered dose. 

---

Amphiphilic CyD Nanoparticles Only a few studies have evaluated the release kinetics from nanoparticles prepared with amphiphilic CyDs [52, 56, 57, 62]. The parameters involved in in vitro release are the nanosphere loading technique, the drug CyD association constant, and the effect of the substitution side. 

---